0001193125-21-101366.txt : 20210331 0001193125-21-101366.hdr.sgml : 20210331 20210331073202 ACCESSION NUMBER: 0001193125-21-101366 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210331 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 21789823 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 8-K 1 d150898d8k.htm FORM 8-K Form 8-K
Zai Lab Ltd false 0001704292 0001704292 2021-03-31 2021-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2021

 

 

ZAI LAB LIMITED

(Exact name of registrant as specified in its charter)

 

 

 

Cayman Islands   001-38205   98-1144595
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

4560 Jinke Road
Bldg. 1, Fourth Floor Pudong
Shanghai, China		   201210
(Address of principal executive offices)   (Zip Code)

+86 21 6163 2588

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

American Depositary Shares, each representing 1 Ordinary Share, par value $0.00006 per share   ZLAB   The Nasdaq Global Market
Indicate by check mark
Ordinary Shares, par value $0.00006 per share*   9688   The Stock Exchange of Hong Kong Limited

*   Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure

On March 31, 2021, Zai Lab Limited issued a joint press release with its partner Deciphera Pharmaceuticals, Inc. announcing that the China National Medical Products Administration has approved the New Drug Application for QINLOCK® (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumors who have received prior treatment with three or more kinase inhibitors, including imatinib.

The full text of this joint press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description

99.1    Press Release issued by Zai Lab Limited on March 31, 2021.
104    The cover page of this Current Report on Form 8-K is formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ZAI LAB LIMITED
By:  

/s/ Billy Cho

 

Billy Cho

Chief Financial Officer

Date: March 31, 2021

EX-99.1 2 d150898dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

  

LOGO

China NMPA Approves QINLOCK® (Ripretinib) for

Treatment of Advanced Gastrointestinal Stromal

Tumors (GIST)

China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST

QINLOCK demonstrated a significant improvement in progression-free survival and a clinically meaningful benefit in overall survival compared to placebo in the pivotal Phase 3 INVICTUS study

QINLOCK approval is the third innovative oncology product approval Zai Lab received in the last 15 months

SHANGHAI, SAN FRANCISCO, CA and WALTHAM, MA, March 31, 2021 — Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Deciphera Pharmaceuticals (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the China National Medical Products Administration (NMPA) has approved its New Drug Application (NDA) for QINLOCK® (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. QINLOCK targets the broad spectrum of KIT and PDGFRµ mutations known to drive GIST.

“Treatment of GIST remains an important unmet medical need in China,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “Approximately 30,000 GIST patients are newly diagnosed each year in China, twice as many as in the U.S. and Europe combined. NMPA’s approval of QINLOCK establishes a new standard of care for treating patients with fourth-line GIST in China. We appreciate the NMPA’s rapid and thorough assessment of QINLOCK. We look forward to working closely with our partner, Deciphera, to introduce this new treatment option to benefit many more patients who are suffering from advanced GIST in Greater China.”

“We congratulate Zai on gaining this important approval,” said Steve Hoerter, President and Chief Executive Officer of Deciphera. “QINLOCK is a new standard of care for patients with fourth-line GIST, and we’re excited to work with our partner Zai as they deliver this innovative medicine to patients in China.”

“The approval of QINLOCK in China is a significant milestone for the GIST community,” said Dr. Shukui Qin, Chief Physician of Cancer Center, Nanjing Jinling Hospital, Senior Vice President of the Chinese Society of Clinical Oncology. “Many GIST patients, who initially responded to traditional tyrosine kinase inhibitors, ultimately developed tumor progression due to secondary mutations. QINLOCK may potentially alter the treatment landscape for patients in China with GIST.”

“Based on the pivotal Phase 3 INVICTUS study, QINLOCK demonstrated compelling clinical benefit in progression-free and overall survival, and was shown to have a favorable safety profile in treating advanced GIST patients,” said Dr. Lin Shen, Vice President of Clinical Oncology at Beijing Cancer Hospital. “We look forward to making this innovative therapy available to patients as soon as possible.”

Deciphera and Zai Lab are also exploring the use of QINLOCK to treat patients with second-line GIST. Deciphera has completed target enrollment in the Phase 3 INTRIGUE study of QINLOCK in patients with second-line GIST, with top-line results anticipated in the second half of 2021.

About QINLOCK (ripretinib)

QINLOCK is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRµ mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop. QINLOCK inhibits primary and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18 involved in GIST, as well as the primary exon 17 D816V mutation. QINLOCK also inhibits primary PDGFRµ mutations in exons 12, 14, and 18, including the exon 18 D842V mutation, involved in a subset of GIST.

In March 2021, the NMPA approved QINLOCK for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. In March 2021, the Hong Kong Department of Health approved QINLOCK in Hong Kong for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib. In May 2020, the U.S. FDA approved QINLOCK for the treatment of adult patients with advanced GIST who received prior treatment with three or more kinase inhibitors, including imatinib. It is also approved by Health Canada for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib and by the Australian Therapeutic Goods Administration for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Zai Lab has an exclusive license agreement with Deciphera for the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan).

About the INVICTUS Phase 3 Study

INVICTUS is a Phase 3 randomized, double-blind, placebo-controlled, international, multicenter clinical study evaluating the safety, tolerability, and efficacy of QINLOCK compared to placebo in patients with advanced GIST whose previous therapies have included imatinib, sunitinib, and regorafenib. Patients were randomized 2:1 to either 150 mg of QINLOCK or placebo once daily. The primary efficacy endpoint is progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST). The median PFS in the study was 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate (ORR) and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504). QINLOCK also demonstrated a median OS of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36).

Important Safety Information

There are no contraindications for QINLOCK. The most common adverse reactions (³20%) were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (PPES), and vomiting. The most common Grade 3 or 4 laboratory abnormalities (³4%) were increased lipase and decreased phosphate.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit www.deciphera.com or follow us on LinkedIn and Twitter (@Deciphera).

Zai Lab Forward-Looking Statements

This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for commercializing QINLOCK in Greater China and other statements containing words such as “potentially”, “anticipates,” “believes,” “expects,” “plan” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab’s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab’s ability to successfully commercialize and generate revenue from its approved products; (2) Zai Lab’s ability to finance its operations and business initiatives and obtain funding for such activities, (3) Zai Lab’s results of clinical and pre-clinical development of its product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab’s product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on general economic, regulatory and political conditions and (6) other factors discussed in Zai Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 1, 2021, and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab’s expectations and assumptions to change and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab’s views as of any date subsequent to the date of this press release.

Deciphera Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations regarding top-line data from our Phase 3 INTRIGUE study in second-line GIST, the possible benefits of QINLOCK in GIST patients, and expanding the geographic reach of QINLOCK. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, our ability to successfully demonstrate the efficacy and safety of our drug candidates and in additional indications for our existing drug, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, our ability to build and scale our operations to support growth in additional geographies, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized, our ability to comply with healthcare regulations and laws, our ability to obtain, maintain and enforce our intellectual property rights, any or all of which may affect the initiation, timing and progress of clinical studies and the timing of and our ability to obtain additional regulatory approvals, and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

+86 137 6151 2501

billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006 ext. 315 / 364

rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Mike Zanoni

Endurance Advisors, on behalf of Zai Lab

610-442-8570

mzanoni@enduranceadvisors.com

DECIPHERA CONTACTS:

Investors: Jen Robinson

Deciphera Pharmaceuticals, Inc.

781-906-1112

jrobinson@deciphera.com

Media: David Rosen

Argot Partners, on behalf of Deciphera

212-600-1902

David.Rosen@argotpartners.com

 

LOGO

Zai Lab Limited

EX-101.SCH 3 zlab-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 zlab-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 zlab-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g150898fat8.jpg GRAPHIC begin 644 g150898fat8.jpg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g150898g0324122151140.jpg GRAPHIC begin 644 g150898g0324122151140.jpg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g150898g0324122151421.jpg GRAPHIC begin 644 g150898g0324122151421.jpg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end XML 9 d150898d8k_htm.xml IDEA: XBRL DOCUMENT 0001704292 2021-03-31 2021-03-31 Zai Lab Ltd false 0001704292 8-K 2021-03-31 E9 001-38205 98-1144595 4560 Jinke Road Bldg. 1 Fourth Floor Pudong Shanghai CN 201210 86 21 6163 2588 false false false false American Depositary Shares, each representing 1 Ordinary Share, par value $0.00006 per share ZLAB NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Mar. 31, 2021
Cover [Abstract]  
Entity Registrant Name Zai Lab Ltd
Amendment Flag false
Entity Central Index Key 0001704292
Document Type 8-K
Document Period End Date Mar. 31, 2021
Entity Incorporation State Country Code E9
Entity File Number 001-38205
Entity Tax Identification Number 98-1144595
Entity Address, Address Line One 4560 Jinke Road
Entity Address, Address Line Two Bldg. 1
Entity Address, Address Line Three Fourth Floor Pudong
Entity Address, City or Town Shanghai
Entity Address, Country CN
Entity Address, Postal Zip Code 201210
City Area Code 86 21
Local Phone Number 6163 2588
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title American Depositary Shares, each representing 1 Ordinary Share, par value $0.00006 per share
Trading Symbol ZLAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d150898d8k.htm d150898dex991.htm zlab-20210331.xsd zlab-20210331_lab.xml zlab-20210331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d150898d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d150898d8k.htm" ] }, "labelLink": { "local": [ "zlab-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zlab-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zlab-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zlab", "nsuri": "http://zailab.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d150898d8k.htm", "contextRef": "duration_2021-03-31_to_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d150898d8k.htm", "contextRef": "duration_2021-03-31_to_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://zailab.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001193125-21-101366-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-101366-xbrl.zip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end